Spoken Alpha
AMGN
AMGEN INC
Overview
Amgen discovers, develops, manufactures and delivers medicines to treat serious diseases, with a focus on oncology, cardiovascular disease, inflammation and bone health.
AMGEN INC is a Healthcare company operating in Drug Manufacturers - General with a $186.05B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-3013 Q&A exchanges
- Q4 FY2025Earnings2026-02-0322 Q&A exchanges
- Q3 FY2025Earnings2025-11-0412 Q&A exchanges
- Q2 FY2025Earnings2025-08-0516 Q&A exchanges
- Q1 FY2025Earnings2025-05-0116 Q&A exchanges
- Q4 FY2024Earnings2025-02-0418 Q&A exchanges
- Q3 FY2024Earnings2024-10-3020 Q&A exchanges
- Q2 FY2024Earnings2024-08-0615 Q&A exchanges
- Q1 FY2024Earnings2024-05-0117 Q&A exchanges
- Q4 FY2023Earnings2024-02-0622 Q&A exchanges
- Q3 FY2023Earnings2023-10-3117 Q&A exchanges
- Q2 FY2023Earnings2023-08-0318 Q&A exchanges
- Q1 FY2023Earnings2023-04-2716 Q&A exchanges
- Q4 FY2022Earnings2023-01-3118 Q&A exchanges
- Q3 FY2022Earnings2022-11-0320 Q&A exchanges
- Q2 FY2022Earnings2022-08-0420 Q&A exchanges
- Q1 FY2022Earnings2022-04-2720 Q&A exchanges
- Q4 FY2021Earnings2022-03-0125 Q&A exchanges
- Q3 FY2021Earnings2021-11-0228 Q&A exchanges
- Q2 FY2021Earnings2021-08-0331 Q&A exchanges
- Q1 FY2021Earnings2021-04-2828 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $5.55—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $5.55 | — | — | — | — | EODHD |
Source: EODHD. AMGN reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AMGN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.00 | $2.04 | -1.9% | -2.3% | -0.5% |
| Q4 FY2026 | $1.87 | $1.91 | -2.3% | +0.4% | -1.6% |
| Q3 FY2026 | $1.89 | $2.07 | -8.8% | -0.9% | -0.3% |
| Q2 FY2026 | $1.87 | $2.10 | -11.0% | -6.5% | -8.8% |
| Q1 FY2025 | $1.94 | $1.95 | -0.5% | -4.5% | -2.5% |
| Q4 FY2025 | $1.84 | $2.12 | -13.2% | -3.9% | -5.8% |
| Q3 FY2025 | $1.98 | $1.99 | -0.7% | -2.6% | -1.3% |
| Q2 FY2025 | $2.15 | $2.23 | -3.6% | -5.5% | -5.2% |
| Q1 FY2024 | $1.93 | $2.00 | -3.3% | -4.6% | -5.2% |
| Q4 FY2024 | $1.96 | $2.04 | -3.7% | -8.1% | -7.2% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Maintained2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Maintained2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Maintained2025-10-15
- Q2 FY2025Maintained2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Robert A BradwayCEO3 mo20 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- Peter H GriffithCFO3 mo20 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Nancy A GrygielSVP & CCO7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q3 FY2026
- David M ReeseEVP & Chief Technology Officer7 mo11 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Derek MillerSVP, Human Resources3 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2026
- Jonathan P GrahamEVP & Gen. Counsel & Sec.3 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AMGN.
$ curl https://api.spokenalpha.com/v1/companies/AMGNFAQ
Frequently asked about AMGN
Where can I find AMGEN INC's (AMGN) earnings call transcripts?
Spoken Alpha indexes AMGN's earnings call transcripts at https://spokenalpha.com/companies/AMGN. Each call links to attributed speakers and parsed analyst Q&A. AMGEN INC's own investor relations page is at https://investors.amgen.com/.
When was AMGEN INC's most recent earnings call?
AMGEN INC (AMGN) held its most recent earnings call on 2026-04-30, covering fiscal Q1 2026.
What sector is AMGN in?
AMGEN INC (AMGN) operates in the Healthcare sector (Drug Manufacturers - General industry).